Abstract
The aetiology of obesity is multi-factorial. Recent research has identified a novel association between endotoxaemia (circulating lipopolysaccharide in the systemic circulation) and low-grade inflammation in the adipose organ, which may contribute to obesity. The mechanisms for the low-grade elevation of circulating lipopolysaccharide in obesity are poorly understood. Vitamin D has been increasingly recognised for its pleiotropic actions beyond maintenance of musculoskeletal health. The parathyroid-vitamin D axis is altered in obesity. Circulating vitamin D levels are lower in obese individuals. The regulatory role of vitamin D in the immune system and colonic mucosa may explain the under-appreciated contribution of vitamin D deficiency in the obese to the pathogenesis of endotoxaemia and adipose inflammation. We propose a hypothetical model linking metabolic endotoxaemia with vitamin D deficiency in obesity. A therapeutic approach involving the use of probiotics and vitamin D metabolites in the obese is described.
Current Pharmaceutical Design
Title: Vitamin D Deficiency: The Invisible Accomplice of Metabolic Endotoxemia?
Volume: 15 Issue: 23
Author(s): Paul Lee and Lesley V. Campbell
Affiliation:
Abstract: The aetiology of obesity is multi-factorial. Recent research has identified a novel association between endotoxaemia (circulating lipopolysaccharide in the systemic circulation) and low-grade inflammation in the adipose organ, which may contribute to obesity. The mechanisms for the low-grade elevation of circulating lipopolysaccharide in obesity are poorly understood. Vitamin D has been increasingly recognised for its pleiotropic actions beyond maintenance of musculoskeletal health. The parathyroid-vitamin D axis is altered in obesity. Circulating vitamin D levels are lower in obese individuals. The regulatory role of vitamin D in the immune system and colonic mucosa may explain the under-appreciated contribution of vitamin D deficiency in the obese to the pathogenesis of endotoxaemia and adipose inflammation. We propose a hypothetical model linking metabolic endotoxaemia with vitamin D deficiency in obesity. A therapeutic approach involving the use of probiotics and vitamin D metabolites in the obese is described.
Export Options
About this article
Cite this article as:
Lee Paul and Campbell V. Lesley, Vitamin D Deficiency: The Invisible Accomplice of Metabolic Endotoxemia?, Current Pharmaceutical Design 2009; 15 (23) . https://dx.doi.org/10.2174/138161209788923895
DOI https://dx.doi.org/10.2174/138161209788923895 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Flavonoids and Anthranquinones as Xanthine Oxidase and Monoamine Oxidase Inhibitors: A New Approach Towards Inflammation and Oxidative Stress
Current Topics in Medicinal Chemistry Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism Human Immunodeficiency Virus (HIV) and Stroke: Targets for Intervention
Infectious Disorders - Drug Targets Rheumatological Manifestations in Diabetes Mellitus
Current Diabetes Reviews Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder
Current Neuropharmacology Cognitive Impairment in the Septic Brain
Current Neurovascular Research Patent Selections
Recent Patents on Drug Delivery & Formulation Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice
Current Medicinal Chemistry Leukocyte P2 Receptors: A Novel Target for Anti-inflammatory and Antitumor Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews Why Does Obesity Increase the Risk for Cardiovascular Disease?
Current Pharmaceutical Design The Need for Diagnostic Criteria in Systemic Vasculitis
Current Immunology Reviews (Discontinued) Stem Cells Therapies in Basic Science and Translational Medicine: Current Status and Treatment Monitoring Strategies
Current Pharmaceutical Biotechnology Synthesis and Biological Evaluation of Novel N-[(7-pyridin-4-yl-2, 3- dihydro-benzofuran-2-yl) Methyl]-(4-methyl-1, 2, 3-thiadiazole-5-yl) Formamide as a Potent Immunosuppressant Agent
Letters in Drug Design & Discovery New Antihypertensive Drugs Under Development
Current Medicinal Chemistry Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology Clinical and Forensic Signs Related to Cocaine Abuse
Current Drug Abuse Reviews Rheumatoid Foot and Ankle Surgery
Current Rheumatology Reviews Viewing the Cardiovascular Pathogenicity of Lp(a) from the Pro-Inflammatory Side
Vascular Disease Prevention (Discontinued)